Dateline City:
WHITEHOUSE STATION, N.J.
Immunogenicity non-inferior to GARDASIL for original four HPV types
Merck expects to file Biologics License Application with U.S. FDA in 2013
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that in the pivotal Phase III efficacy study, its
investigational 9-valent HPV vaccine (V503) prevented approximately 97
percent of cervical, vaginal and vulvar pre-cancers caused by HPV types
31, 33, 45, 52, and 58.
Language:
English
Contact:
Media:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more